G2

deepti b.

Founder

Small-Business (50 or fewer emp.)

8/15/2026

"TinyFish Adds Valuable Regional Trial Context with Flexible Budget Controls"

5/5

What do you like best about TinyFish?

What I like most about TinyFish is how well it handles web-based sources that are hard to reach through conventional APIs. In GraftWatch, it helps enrich ClinicalTrials.gov data by adding India-specific registry information, non-U.S. trial records, and sponsor updates. That extra layer of regional context makes the tool more valuable for researchers who need more than just global trial data. I also appreciate that TinyFish can be used selectively, with budget controls, instead of adding unnecessary cost to every search. Review collected by and hosted on G2.com.

What do you dislike about TinyFish?

The main thing I dislike is that integrating TinyFish can require more setup and clarification than a conventional API, especially when working with web sources that change their structure. The API contract and response formats also need to be very clear for production use. In GraftWatch, I had to add budget limits and fallback handling so a failed or expensive enrichment request would no Review collected by and hosted on G2.com.

What problems is TinyFish solving and how is that benefiting you?

TinyFish helps solve the problem of fragmented clinical-trial information. ClinicalTrials.gov is valuable, but it does not always provide India-specific registrations, non-US trial details, or sponsor-reported updates. TinyFish can search these harder-to-structure web sources and enrich the core trial records.

For GraftWatch, this improves the India-relevance of each trial and reduces the amount of manual registry and sponsor-site searching required. It helps researchers move from a global list of trials to a more practical shortlist of studies that may be relevant and accessible to Indian patients. Review collected by and hosted on G2.com.